Search | OpenScholar

Search results

374 results found

Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine. 2022 Mar 2;97:47-51. doi: 10.1016. Epub 2022 Mar 2.PMID: 35299070.

Publication: Journal Article

Hauser, RA, H Barkay, A Wilhelm, M Wieman, JM Savola, and MF Gordon. 2022. “Minimal Clinically Important Change in Abnormal Involuntary Movement Scale Score in Tardive Dyskinesia As Assessed in Pivotal Trials of Deutetrabenazine. 2022 Mar 2;97:47-51. Doi: 10.1016. Epub 2022 Mar 2.PMID: 35299070.”. Parkinsonism Relat Disord.

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease. 2022 Mar 18;8(1):29. doi: 10.1038/s41531-022-00291-1. PMID: 35304480.

Publication: Journal Article

Hauser, RA, J Lytle, AE Formella, and CM Tanner. 2022. “Amantadine Delayed Release/Extended Release Capsules Significantly Reduce OFF Time in Parkinson’s Disease. 2022 Mar 18;8(1):29. Doi: 10.1038/S41531-022-00291-1. PMID: 35304480.”. NP J Parkinsons Dis.

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. 2022 Dec;175(12):1666-1674. doi: 10.7326/M22-1438. Epub 2022 Nov 8. PMID: 36343348

Publication: Journal Article

Camilleri, M, T Subramanian, F Pagan, S Isaacson, R Gil, RA Hauser, M Feldman, and M Goldstein. 2022. “Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. 2022 Dec;175(12):1666-1674. Doi: 10.7326/M22-1438. Epub 2022 Nov 8. PMID: 36343348”. Ann Intern Med.

The Clinical Development of Levodopa Inhalation Powder. 2023 Mar-Apr 01;46(2):66-78. doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. PMID: 36715241

Publication: Journal Article

Hauser, RA, PA LeWitt, CH Waters, DG Grosset, and B Blank. 2023. “The Clinical Development of Levodopa Inhalation Powder. 2023 Mar-Apr 01;46(2):66-78. Doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. PMID: 36715241”. Clin Neuropharmacol.

Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics 2020;17:1339-1365.

Publication: Journal Article

Aradi, SD, and RA Hauser. 2020. “Medical Management and Prevention of Motor Complications in Parkinson’s Disease. Neurotherapeutics 2020;17:1339-1365.”. Neurotherapeutics.

Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. Parkinsonism Relat Disord 2020;80:127-132.

Publication: Journal Article

Mills, KA, RB Schneider, M Saint-Hilaire, GW Ross, RA Hauser, AE Lang, MJ Halverson, et al. 2020. “Cognitive Impairment in Parkinson’s Disease: Associations Between Subjective and Objective Cognitive Decline in a Large Longitudinal Study. Parkinsonism Relat Disord 2020;80:127-132.”. Parkinsonism Relat Disord.

Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. Front Neurol. 2020;11:576117.

Publication: Journal Article

Hauser, RA, and . 2020. “Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. Front Neurol. 2020;11:576117.”. Front Neurol.

On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep;133(7):721-727. doi: 10.1080/00325481.2021.1936087.

Publication: Journal Article

Hauser, RA, PA LeWitt, and CL Comella. 2021. “On Demand Therapy for Parkinson’s Disease Patients: Opportunities and Choices. Postgrad Med. 2021 Sep;133(7):721-727. Doi: 10.1080/00325481.2021.1936087.”. Postgrad Med.

A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. Sensors (Basel). 2021 Aug 12;21(16):5437. doi: 10.3390/s21165437. PMID: 34450879.

Publication: Journal Article

Rupprechter, S, G Morinan, Y Peng, T Foltynie, K Sibley, RS Weil, LA Leyland, et al. 2021. “A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson’s Disease. Sensors (Basel). 2021 Aug 12;21(16):5437. Doi: 10.3390/S21165437. PMID: 34450879.”. Sensors (Basel).

Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663-1675. doi: 10.3233/JPD-212672. PMID: 34486986

Publication: Journal Article

Hauser, RA, N Hattori, H Fernandez, SH Isaacson, H Mochizuki, O Rascol, F Stocchi, et al. 2021. “Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, As Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663-1675. Doi: 10.3233/JPD-212672. PMID: 34486986”. J Parkinsons Dis.